phase readout
saveNCT04602598: Zanubrutinib in Patients With IgG4-Related Disease
community read0 votes
Sponsor: Matthew C. Baker. Phase: PHASE2. Conditions: IgG4 Related Disease
view source ↗Data sources
last refreshed 6h ago
Found something off?
same company · ±60 days · 6
- earningsBeOne Medicines Ltd. earningsNov 5, 2026
- earningsBeOne Medicines Ltd. earningsAug 5, 2026
- earningsBeOne Medicines Ltd. earningsMay 6, 2026
- phase 1 completionBG-89894: BeOne Medicines AG — BG-89894 (Phase I Trial Completion)Apr 30, 2026
- phase 1 initiationBGC-0979: BeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)Apr 30, 2026
- approvalTEVIMBRA (TISLELIZUMAB-JSGR) — FDA approvalDec 9, 2025
related news · 8
- statBeOne, Hengrui top list of China’s most powerful drugmakers
- biospaceChina has a clear shot to 2030 goals, though economic, cultural barriers remain
- fiercebiotechCould we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
- biospaceRevMed’s Rasonque shatters analyst estimates with $198M quarter
- biospaceWith MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
- biospace6 potential blockbusters that could pave China’s path to 2030 ambitions
- fiercebiotechNurix drops one BTK degrader as momentum builds behind Roche-partnered option
- biospace5 biggest venture capital raises of Q3 2026
comments(0)
5-min edit window · permanent after that